Surveillance of Complex Renal Cysts - The SOCRATIC Study (SOCRATIC)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04558593 |
|
Recruitment Status :
Recruiting
First Posted : September 22, 2020
Last Update Posted : March 8, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
One third of individuals aged >60 years will be diagnosed with at least one renal cyst following abdominal imaging. These cystic lesions are categorized according to the Bosniak classification which categorizes cysts according to their degree of complexity and risk of malignancy. Growing evidence suggests that a significant proportion of Bosniak III and IV cysts are benign and that the malignant ones present low metastatic potential. Since renal surgery carries substantial morbidity (20%) and potential mortality (0.5%), active surveillance has gained attention as a potential tradeoff to surgery to overcome overtreatment. Therefore, prospective studies of long-term follow-up are needed to confirm the oncologic safety of this strategy for patients with Bosniak III/IV cysts.
This is an multicenter prospective observational longitudinal study. The main objective is to compare the 5-year follow-up cancer-specific survival between the active surveillance and the surgical groups.
| Condition or disease | Intervention/treatment |
|---|---|
| Complex Renal Cyst | Procedure: Active surveillance Procedure: Surgery |
Background: One in three patients over 60 years old will be diagnosed with a renal cyst following abdominal imaging. Traditionally, experts have recommended that complex cystic lesions (also known as Bosniak III - IV cysts) should be surgically removed, but recent evidences suggest that many are benign or have low metastatic potential. Thus, active surveillance which involves close follow-up of a patient's condition, was proposed as a tradeoff option to surgery.
Design: Multicenter observational longitudinal prospective cohort study
Objectives: The goal of this multicenter project is to conduct a prospective study with a 5-year follow-up to confirm the oncologic outcomes of active surveillance in the management of complex cysts. The main objectives are: 1) to compare the 5-year cancer specific survival between cysts managed by surgery and active surveillance; 2) to evaluate disease progression; 3) to evaluate patient's well-being according to each management strategy; and 4) to compare the 5-year healthcare cost of both management approaches.
Study population: Patients incidentally diagnosed with a Bosniak III and/or IV cysts, who are deemed to have at least 5 years of life, and who opted to be managed by either surgery or active surveillance. (N=330)
Follow-up: Patients will DECIDE if they want to have a surgery or to be followed by active surveillance. All patients will be followed as per standard of care with either semi-annual and annual visits. Research visits will serve to evaluate vital status and quality of life scores (through validated questionnaires). Patients on active surveillance will also be assessed for cyst progression and will be offered invasive or systemic therapy if progression is observed.
| Study Type : | Observational |
| Estimated Enrollment : | 330 participants |
| Observational Model: | Cohort |
| Time Perspective: | Prospective |
| Official Title: | Surveillance of Complex Renal Cysts - The SOCRATIC Study |
| Actual Study Start Date : | February 2, 2021 |
| Estimated Primary Completion Date : | December 20, 2029 |
| Estimated Study Completion Date : | December 20, 2030 |
| Group/Cohort | Intervention/treatment |
|---|---|
|
active surveillance
220 participants will be included in the active surveillance group. Active surveillance is close monitoring (every 6 months the first 3 years following diagnosis and annually the following years), done per standard of care Close monitoring include: abdominal imaging (ultrasound, CT or MRI), chest X-ray or CT scan and blood tests
|
Procedure: Active surveillance
Per standard of care: Imaging and blood tests every 6 months (3 first years) and annually (following years) |
|
surgery
110 participants will be included in the surgery group. Surgery is done per standard of care. The type of surgery is at the discretion of the treating physician and may include: partial resection, total resection, thermoablation.
|
Procedure: Surgery
Per standard of care: partial or full resection of the kidney |
- 5-year cancer-specific survival [ Time Frame: from the date of enrollment (defined by signed consent) to the end of follow-up (up to 5 years) ]Defined as kidney cancer survival 5 years after the enrollment
- 5-year overall survival [ Time Frame: from the date of enrollment (defined by signed consent) to the end of follow-up (up to 5 years) ]Defined as survival 5 years after enrollment
- 2-year overall survival [ Time Frame: from the date of enrollment (defined by signed consent) up to 2 years of follow-up ]Defined as survival 2 years after enrollment
- 2-year cancer-specific survival [ Time Frame: from the date of enrollment (defined by signed consent) up to 2 years of follow-up ]Defined as kidney cancer survival 2 years after the enrollment
- Treatment-free survival [ Time Frame: from the date of enrollment (defined by signed consent) up to 2 and 5 years of follow-up ]Defined as survival without treatment (in active surveillance group)
- Discontinuation rate [ Time Frame: from the date of enrollment (defined by signed consent) to the end of follow-up (up to 5 years) ]Defined as the number of people who discontinued active surveillance at the end of the study (over the total)
- Tumor growth rate [ Time Frame: if there is a progression, at the time of imaging (undefined, between 6 months and 5 years post-enrollment) ]Defined by change in volume (cm3 ) and change in maximal diameter measured over time (years). Volume will be calculated using the formula for ellipsoid volume: 0.5326 x length x width x height.
- Tumor progression rate [ Time Frame: if there is a progression, at the time of imaging (undefined, between 3 months and 5 years post-enrollment) ]Defined as the percentage of patients with tumors that have met our pre-specified progression endpoints
- Time to tumor progression (Progression-free survival) [ Time Frame: range of time from enrollment to progression (undefined, between 3 months and 5 years post-enrollment) or end of follow-up (5 years post-enrollment) ]Defined as the time from the date of enrollment to the date where an individual experienced tumor progression or censoring due to lost to follow-up or the end of follow-up period
- Patient and tumor characteristics in correlation with cancer-specific death [ Time Frame: at the baseline visit (no more than 30 days after signed consent) ]Defined as demographic (i.e. age, sex, comorbidities, medical history, etc) and tumor characteristics (i.e. tumor size, tumor complexity, etc) associated with kidney cancer deaths
- Patient and tumor characteristics in correlation with disease progression [ Time Frame: at the baseline visit (no more than 30 days after signed consent) ]Defined as demographic (i.e. age, sex, comorbidities, medical history, etc) and tumor characteristics (i.e. tumor size, tumor complexity, etc) associated with disease progression.
- Perceived health change over time [ Time Frame: range of time from enrollment to end of follow-up (maximum 5 years post-enrollment) ]Defined as the change in EQ5D-5L scores over time (enrollment to censoring due to lost of follow-up or the end of follow-up period).
- Quality of life change over time [ Time Frame: range of time from enrollment to end of follow-up (maximum 5 years post-enrollment) ]Defined as the change in short form health survey (SF-12) scores over time (enrollment to censoring due to lost of follow-up or the end of follow-up period).
- Anxiety change over time [ Time Frame: range of time from enrollment to end of follow-up (maximum 5 years post-enrollment) ]Defined as the change in Hospital Anxiety and Depression Scale (HADS) scores over time (enrollment to censoring due to lost of follow-up or the end of follow-up period).
- Health cost [ Time Frame: range of time from enrollment to end of follow-up (maximum 5 years post-enrollment) ]Defined as the total direct (patients) and indirect (healthcare system) cost associated with the management of a complex cyst according to each treatment strategy (active surveillance and surgery).
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- 18 years old and older;
- diagnosed with a Bosniak III or IV cyst (classification 2019);
- size of cystic component ≤7cm;
- cyst wall/septum nodule (obtuse margin of protrusion) ≤3mm for Bosniak III cysts and <10mm for Bosniak IV ;
- solid component acute margin of protrusion ≤2 cm in maximal diameter for Bosniak IV cysts;
- life expectancy >5 years (by physician's estimate);
- diagnosis ≤ 6 months from accrual date;
- currently asymptomatic from the disease;
- deemed fit enough for surgery;
- willingness and ability to complete questionnaires in either French or English;
- able and willing to provide informed consent
Exclusion Criteria:
- history of a hereditary renal cancer syndrome;
- presence of polycystic kidney disease;
- any prior history of RCC;
- received systemic therapy for another malignancy within the 12 months prior to accrual;
- uncontrolled medical illness including infections, hypertension, arrhythmias, heart failure, or myocardial infarction/unstable angina within 6 months that would predispose to immediate surgical therapy;
- metastatic disease or evidence of vascular or nodal disease;
- unwillingness to undergo monitoring and imaging studies;
- any contra-indication(s) to contrast-enhanced imaging (estimated glomerular filtration rate <30min/mL)
- refusing to be co-enrolled in CKCis registry (when applicable in CKCis participating centers)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04558593
| Contact: Amelie Tetu | 819-346-1110 ext 15571 | amelie.tetu.ciussse-chus@ssss.gouv.qc.ca |
| Canada, Alberta | |
| Prostate Cancer Center | Recruiting |
| Calgary, Alberta, Canada, T2V 1P9 | |
| Contact: Lora Mendoza | |
| Principal Investigator: Bimal Bhindi | |
| Canada, Ontario | |
| St-Joseph's Hospital | Not yet recruiting |
| Hamilton, Ontario, Canada | |
| Contact: Camilla Tajzler | |
| Principal Investigator: Anil Kapoor | |
| The Ottawa Hospital | Recruiting |
| Ottawa, Ontario, Canada | |
| Contact: David Yachnin | |
| Principal Investigator: Luke Lavallee | |
| Princess Margaret Hospital | Recruiting |
| Toronto, Ontario, Canada | |
| Contact: Maria Komisarenko | |
| Principal Investigator: Antonio Finelli | |
| Canada, Quebec | |
| Centre intégré de santé et de services sociaux de Chaudière-Appalaches - Hôtel-Dieu de Lévis | Recruiting |
| Lévis, Quebec, Canada, G6V 3Z1 | |
| Contact: Estel Deblois | |
| Principal Investigator: Matthieu Gratton | |
| CHUM | Recruiting |
| Montreal, Quebec, Canada | |
| Contact: Amal Nadiri | |
| Principal Investigator: Jean-Baptiste Lattouf | |
| McGill University Health Centre | Recruiting |
| Montreal, Quebec, Canada | |
| Contact: Christopher Naccache | |
| Principal Investigator: Simon Tanguay | |
| CHU de Québec - Université Laval | Recruiting |
| Québec, Quebec, Canada | |
| Contact: Marilyn Savard | |
| Principal Investigator: Frédéric Pouliot | |
| Centre de recherche du Centre hospitalier Universitaire de Sherbrooke | Recruiting |
| Sherbrooke, Quebec, Canada, J1H 5N4 | |
| Contact: Elsie Morneau 819-346-1110 ext 12827 | |
| Principal Investigator: Patrick O Richard | |
| Principal Investigator: | Patrick O Richard, MD,MSc,FRCSC | Université de Sherbrooke |
| Responsible Party: | Université de Sherbrooke |
| ClinicalTrials.gov Identifier: | NCT04558593 |
| Other Study ID Numbers: |
2020-3522 |
| First Posted: | September 22, 2020 Key Record Dates |
| Last Update Posted: | March 8, 2022 |
| Last Verified: | March 2022 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
renal cyst complex cyst Bosniak III Bosniak IV |
renal masses active surveillance monitoring surgery |
|
Cysts Kidney Diseases, Cystic Neoplasms |
Pathological Conditions, Anatomical Kidney Diseases Urologic Diseases |